Integrated Filing — IndAS



General information about company

Scrip Code 000000
NSE Symbol PAR
MSEI Symbol NOTLISTED
ISIN INE04LG01015
Name of company PAR DRUGS AND CHEMICALS LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 13-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 03-11-2025
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment The Company is primarily engaged in manufacturing of API, which constitute single business segment in terms of Ind AS - 108 on “Operating Segments”. Accordingly, there are no separate reportable segments as per Ind AS - 108.
Start date and time of board meeting 13-11-2025   15:30:00
End date and time of board meeting 13-11-2025   16:28:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 08-05-2025
Indicate Company website link for updated RPT policy of the Company https://pardrugs.com/policies-par-drugs-and-chemicals.php
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
As there is no any outstanding default on loans and debt securities as on 30.09.2025 hence not applicale to the company.



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 2,865.89 5,470.53
Other income 48.01 231.69
Total income 2,913.90 5,702.22
2 Expenses
(a) Cost of materials consumed 1,054.23 2,170.55
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 18.13 35.35
(d) Employee benefit expense 135.49 277.45
(e) Finance costs 5.49 7.12
(f) Depreciation, depletion and amortisation expense 94.11 184.45
(f) Other Expenses
1 Other expenses 1,051.43 2,024.50
Total other expenses 1,051.43 2,024.50
Total expenses 2,358.88 4,699.42
3 Total profit before exceptional items and tax 555.02 1,002.80
4 Exceptional items 0.00 0.00
5 Total profit before tax 555.02 1,002.80
6 Tax expense
7 Current tax 142.06 257.03
8 Deferred tax 0.00 0.00
9 Total tax expenses 142.06 257.03
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 412.96 745.77
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 412.96 745.77
17 Other comprehensive income net of taxes 0.00 0.00
18 Total Comprehensive Income for the period 412.96 745.77
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,230.46 1,230.46
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 3.36 6.06
Diluted earnings (loss) per share from continuing operations 3.36 6.06
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 3.36 6.06
Diluted earnings (loss) per share from continuing and discontinued operations 3.36 6.06
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The standalone financial results of the Company have been prepared in accordance with the Ind AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, other accounting principles generally accepted in India and in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, including relevant circulars issued by the SEBI from time to time. 2. The above quarterly and half year to date financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 13th November, 2025. 3. The Statutory auditors of the company have carried out Limited Review of the above quarterly & half yearly financial results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. 4. The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earning per share (not annualized) in accordance with the Ind AS. 5. Previous Year/Period figures are regrouped / reclassified / rearranged, whenever found necessary to make them comparable with the current period figures. 6. The Company is primarily engaged in manufacturing of API, which constitute single business segment in terms of Ind AS - 108 on “Operating Segments”. Accordingly, there are no separate reportable segments as per Ind AS - 108. 7. The Company does not have any subsidiary, associates or joint venture as on 30th September, 2025; therefore, it has prepared only standalone results as consolidation requirement is not applicable to the Company. 8. The above unaudited financial results of the Company are available on the Company’s website – www.pardrugs.com and on the website of the National Stock Exchange of India Limited (www.nseindia.com), where the Company’s shares are listed. 9. The Status of investors complaints are as follows: I. Pending at the beginning of the quarter - 0 II. Received during the quarter - 0 III. Disposed-off during the quarter - 0 IV. Remaining unresolved at the end of the quarter - 0



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 30-09-2025
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 3,770.48
Capital work-in-progress 6.89
Investment property 0.00
Goodwill 0.00
Other intangible assets 0.00
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 2,672.24
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets 0.00
Total non-current financial assets 2,672.24
Deferred tax assets (net) 0.00
Other non-current assets 59.44
Total non-current assets 6,509.05
2 Current assets
Inventories 527.90
Current financial asset
Current investments 0.00
Trade receivables, current 1,762.80
Cash and cash equivalents 3,385.56
Bank balance other than cash and cash equivalents 0.00
Loans, current 8.78
Other current financial assets 0.00
Total current financial assets 5,157.14
Current tax assets (net) 542.62
Other current assets 15.64
Total current assets 6,243.30
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 12,752.35
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,230.46
Other equity 9,412.80
Total equity attributable to owners of parent 10,643.26
Non controlling interest
Total equity 10,643.26
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities 0.00
Total non-current financial liabilities 0.00
Provisions, non-current 0.00
Deferred tax liabilities (net) 358.00
Deferred government grants, Non-current 0.00
Other non-current liabilities 0.00
Total non-current liabilities 358.00
Current liabilities
Current financial liabilities
Borrowings, current 0.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 47.10
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 855.14
Total Trade payable 902.24
Other current financial liabilities 0.00
Total current financial liabilities 902.24
Other current liabilities 107.19
Provisions, current 741.66
Current tax liabilities (Net) 0.00
Deferred government grants, Current 0.00
Total current liabilities 1,751.09
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 2,109.09
Total equity and liabilites 12,752.35
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2025 01-04-2025
Date of end of reporting period 30-09-2025 30-09-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 30-09-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 1,002.80
Adjustments for reconcile profit (loss)
Adjustments for finance costs 0.00
Adjustments for decrease (increase) in inventories 82.69
Adjustments for decrease (increase) in trade receivables, current (91.39)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (2.39)
Adjustments for decrease (increase) in other non-current assets (5.03)
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (186.90)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (2.56)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 184.45
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 26.66
Adjustments for provisions, non-current (26.66)
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for interest income 53.88
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) (0.06)
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (75.07)
Net cash flows from (used in) operations 927.73
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 118.26
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 809.47
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 1.83
Purchase of property, plant and equipment 72.11
Proceeds from sales of investment property 0.00
Purchase of investment property 165.23
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 53.88
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (181.63)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 0.00
Payments of lease liabilities 0.00
Dividends paid 0.00
Interest paid 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 0.00
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 627.84
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 627.84
Cash and cash equivalents cash flow statement at beginning of period 2,757.72
Cash and cash equivalents cash flow statement at end of period 3,385.56





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Par Drugs And Chemicals Limited Falgunbhai V Savani Managing Director Remuneration Nil 25.75 2.97 2.99 Textual Information(1)
2 Par Drugs And Chemicals Limited Falgunbhai V Savani Managing Director Any other transaction Director Sitting Fees Nil 0.10 0.00 0.00 Textual Information(2)
3 Par Drugs And Chemicals Limited Jigneshbhai V Savani Director & CEO Remuneration Nil 25.75 3.15 3.14 Textual Information(3)
4 Par Drugs And Chemicals Limited Jigneshbhai V Savani Director & CEO Any other transaction Director Sitting Fees Nil 0.05 0.00 0.00 Textual Information(4)
5 Par Drugs And Chemicals Limited Ghanshyambhai B Savani Prodcution Head (Promoter Group) Remuneration Nil 25.75 0.00 4.29
6 Par Drugs And Chemicals Limited Savani Prathambhai Ghanshyambhai Relative of Promoter Group (Son of Ghanshyambhai B. Savani) Remuneration Nil 2.14 0.25 0.27
7 Par Drugs And Chemicals Limited Sanket Bhupendrabhai Trivedi Company Secretary Remuneration Nil 4.37 0.52 0.57
8 Par Drugs And Chemicals Limited Chintan Pratapbhai Chauhan Chief Financial Officer Remuneration Nil 4.03 0.48 0.53
9 Par Drugs And Chemicals Limited Naynaben J Savani Non-Executive Director Any other transaction Director Sitting Fees Nil 0.00 0.05 0.00 Textual Information(5)
10 Par Drugs And Chemicals Limited Kajal Chitanbhai Vaghani Independent Director Any other transaction Director Sitting Fees Nil 0.10 0.23 0.00 Textual Information(6)
11 Par Drugs And Chemicals Limited Krishna Mitulbhai Shah Independent Director Any other transaction Director Sitting Fees Nil 0.10 0.27 0.00 Textual Information(7)
12 Par Drugs And Chemicals Limited Pravin Manjibhai Bhayani Independent Director Any other transaction Director Sitting Fees Nil 0.10 0.00 0.00 Textual Information(8)
13 Par Drugs And Chemicals Limited Pravin Manjibhai Bhayani Independent Director Remuneration Nil 12.00 0.57 1.80 Textual Information(9)
14 Par Drugs And Chemicals Limited Bintal Bhaveshkumar Shah Independent Director Any other transaction Director Sitting Fees Nil 0.05 0.16 0.00 Textual Information(10)
15 Par Drugs And Chemicals Limited PHAL-JIG FINE CHEMICALS PRIVATE LIMITED Enterprise in which significant influence is exercised by KMP Any other transaction Part Payment of Consideration for purchase of Business unit 9,500.00 Nil 0.00 51.00 51.00 Textual Information(11)
Total value of transaction during the reporting period 100.29



Text Block

Textual Information(1) By considering the suggestion and approval of Nomination & Remuneration Committee and approval of Audit Committee held on 16/08/2023, the Board at its meeting held on 17/08/2023 considered and approved re-appointment and fixed remuneration payable, which is subsequently approved by the shareholders for a period of 5 years w.e.f. 26th Day of November, 2023 to 25th Day of November, 2028 in the 24th Annual General Meeting held on Saturday, 16th Day of September, 2023 at 11:00 A.M. at Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, India.
Textual Information(2) By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.
Textual Information(3) By considering the suggestion and approval of Nomination & Remuneration Committee and approval of Audit Committee held on 16/08/2023, the Board at its meeting held on 17/08/2023 considered and approved re-appointment and fixed remuneration payable, which is subsequently approved by the shareholders for a period of 5 years w.e.f. 26th Day of November, 2023 to 25th Day of November, 2028 in the 24th Annual General Meeting held on Saturday, 16th Day of September, 2023 at 11:00 A.M. at Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, India.
Textual Information(4) By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.
Textual Information(5) By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.
Textual Information(6) By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.
Textual Information(7) By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.
Textual Information(8) By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.
Textual Information(9) By considering the suggestion and approval of Nomination & Remuneration Committee and approval of Audit Committee held on 16/08/2024, the Board at its meeting held on 17/08/2024 considered and approved remuneration payable, which is subsequently approved by the shareholders for the period of one year w.e.f. 1st October, 2024 to 30th September, 2025 in the 25th Annual General Meeting held on Saturday, 21st Day of September, 2024 at 11:00 A.M. at Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, India
Textual Information(10) By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.
Textual Information(11) By considering the suggestion and approval of Audit Committee and Board meeting held on 11/01/2025 considered and approved the transaction , which is subsequently approved by the shareholders in the Extra-Ordinary General Meeting (“EGM”) (Meeting No. 02/EGM/2024-25) of the Members of PAR DRUGS AND CHEMICALS LIMITED (“Company”) held on Wednesday, 12th Day of February, 2025 at 3:00 P.M. (IST) through Video Conferencing (“VC”) / Other Audio Visual Means (“OAVM”)